CMS finalized a new Unique Device Identifier measure in the FY 2027 IPPS final rule, with the first electronic health record reporting period beginning in calendar year 2027. Eligible hospitals and critical access hospitals will attest that they used certified electronic health record technology to electronically capture and store the complete UDI for each covered implantable device used in patient care. The measure is part of the Medicare Promoting Interoperability Program.
The rule is aimed at the patient record, but the work starts much earlier. Before an implant can be captured in the chart, someone has to receive it, identify it, assign it to a case, move it through a warehouse or field location, and confirm what was actually opened and used. That is where many device records become unreliable.
This is not a new barcode mandate for every distributor, manufacturer, or 3PL. CMS did not prescribe barcode scanners, real-time location, Bluetooth, or any particular inventory system. But the final rule raises the standard for the result: device identity must be complete, discrete, and usable. A clean record in the EHR is difficult to produce when the physical supply chain still depends on memory, paper pick lists, and a text from the rep.
The clinical capture point is not the beginning
The last scan gets most of the attention because it is closest to the patient. A circulating nurse, implant coordinator, or other member of the surgical team identifies the device and associates its UDI with the procedure. That moment matters. It is also the point at which a weak upstream process becomes visible.
Consider a common sequence. A distributor receives several sizes of an implant family and assigns them to a tote. A field representative picks up the tote for an orthopedic case. The tote arrives at a hospital or ASC, where staff confirm some contents but not all of them. During the procedure, a different size is opened than the one listed on the preliminary pick sheet. The used implant is documented, but the remaining contents are returned under a general tote identifier. Later, the distributor's inventory still shows the original allocation.
Each individual step may look reasonable. Together, they create competing versions of the truth. The hospital has a patient record. The rep has a case note. The distributor has an inventory ledger. The 3PL has a delivery event. None of those records necessarily proves that the same physical device moved through the full chain.
FDA describes UDI as a way to support more accurate adverse event reporting, reduce medical errors, improve device-use data, and manage recalls more effectively. The agency also notes that those benefits depend on adoption across manufacturers, distributors, providers, health systems, and other stakeholders. The identifier is standardized. The operating process around it is not.
The practical distinction is simple: UDI answers what the device is. Operational traceability also needs to answer where it was, who had it, which case it supported, whether it was consumed, and what remains available.
Movement and use are two different records
Medical device teams often treat movement as a proxy for use. If a tote reached the hospital, the assumption is that its contents supported the case. If an implant was assigned to a procedure, the assumption is that it was available when needed. If a field rep says a kit was returned, the inventory record is closed.
Those assumptions are where reconciliation work accumulates.
A tracked tote can show that a kit reached a hospital without proving that the kit was complete. An inventory record can show that an implant was allocated without proving that it was opened. A case note can list a device without showing whether the corresponding stock was removed from the correct location. The closer the organization gets to billing, replenishment, recall response, or patient follow-up, the more expensive these gaps become.
For distributors and manufacturers, the problem is not limited to compliance. It affects utilization and working capital. A device that is physically sitting in a field location but remains assigned to a closed case is not available in the same way as stock that has been received, reconciled, and placed back into an active inventory pool. A tote that returns with unverified contents may appear ready while still requiring a manual check. A missing production identifier can turn a routine replenishment into a research project.
The right workflow keeps the device record close to the work. A field team should be able to capture the barcode at the case rather than write it down for later entry. Warehouse and SPD staff should be able to record what was received, moved, or found while they are handling the asset. The resulting record should stay connected to the named tote, implant inventory, case activity, and location history.
That does not eliminate judgment. A person still decides whether an implant was used, returned, damaged, or held for review. The difference is that the decision is written into the same operational record instead of being reconstructed from separate spreadsheets and messages.
The 2027 measure changes the starting line
CMS finalized the UDI measure on August 4, 2026. Beginning with the calendar year 2027 EHR reporting period, eligible hospitals and critical access hospitals will attest that they electronically captured and stored the complete UDI for covered implantable devices used for patient care. The measure is about EHR capture, but it creates a sharper question for the organizations supplying those hospitals: can the upstream data arrive in a form that clinical teams can trust?
That question will be especially important across networks where inventory crosses organizational boundaries. A manufacturer may own the implant. A distributor may stage it. A 3PL may transport it. A field representative may bring it to the case. The hospital may document it. Each party can perform its own task correctly and still leave the next party with an incomplete record.
There is also a timing problem. The hospital often discovers the data gap at the most compressed point in the workflow, when the patient is in the room and the team is trying to confirm the device. The distributor discovers it later, when a tote returns without a clear usage record. The manufacturer may discover it later still, when a recall, complaint, or replenishment request requires production-level detail.
That is why the useful preparation is not simply to ask whether an organization owns a scanner. The better questions are operational:
- Can the team identify the specific implant stock assigned to a tote or case?
- Can staff record usage at the point of work without a later desk pass?
- Can the organization distinguish an implant that moved from one that was actually consumed?
- Can a field manager reconcile the case record with the physical contents returned?
- Can operations see which location, person, or handoff still needs attention?
Asset records, location history, mobile GS1 capture, and activity trails do not replace the hospital's EHR. They support the part of the workflow that happens before the implant record reaches the chart. That upstream layer is where a device is named, assigned, moved, observed, and reconciled.
The larger lesson from the CMS measure is not that every organization needs the same technology. It is that device identity cannot be treated as a final documentation task. The record starts when the implant enters the operational chain and becomes more reliable every time someone records what happened at the point of work.
By 2027, hospitals will be asked to attest to complete UDI capture for covered implants. The teams that make that possible will not be working only in the operating room. They will be in the warehouse, on the truck, at the ASC receiving dock, beside the sterile processing handoff, and with the field representative closing the case. The chart may be where the identifier ends up. The evidence begins on the dock.
Sources: CMS FY 2027 IPPS final rule and the FDA overview of UDI benefits.
